New option for 1. line treatment of advanced oesophagal squamous cell carcinoma – 29. Month Follow-up
At the ASCO GI meeting, the 29-month follow-up results from the CheckMate 648 study showed a great improvement in survival and long-lasting responses when combining nivolumab with chemotherapy and nivolumab with ipilimumab for patients with advanced oesophagal squamous cell carcinoma. Ken Kato from the National Cancer Center Hospital in Tokyo, Japan, discussed these results in greater depth in this MEDTalk.
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.